Tyra Biosciences (TYRA) Competitors $15.87 -0.34 (-2.10%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TYRA vs. MLTX, HCM, AGIO, DYN, VRNA, PTCT, EWTX, BHC, MRUS, and XENEShould you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include MoonLake Immunotherapeutics (MLTX), HUTCHMED (HCM), Agios Pharmaceuticals (AGIO), Dyne Therapeutics (DYN), Verona Pharma (VRNA), PTC Therapeutics (PTCT), Edgewise Therapeutics (EWTX), Bausch Health Companies (BHC), Merus (MRUS), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Tyra Biosciences vs. MoonLake Immunotherapeutics HUTCHMED Agios Pharmaceuticals Dyne Therapeutics Verona Pharma PTC Therapeutics Edgewise Therapeutics Bausch Health Companies Merus Xenon Pharmaceuticals Tyra Biosciences (NASDAQ:TYRA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership. Is TYRA or MLTX more profitable? MoonLake Immunotherapeutics' return on equity of -15.54% beat Tyra Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Tyra BiosciencesN/A -24.56% -23.31% MoonLake Immunotherapeutics N/A -15.54%-15.09% Does the MarketBeat Community prefer TYRA or MLTX? MoonLake Immunotherapeutics received 31 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 80.52% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.81% of users gave Tyra Biosciences an outperform vote. CompanyUnderperformOutperformTyra BiosciencesOutperform Votes3173.81% Underperform Votes1126.19% MoonLake ImmunotherapeuticsOutperform Votes6280.52% Underperform Votes1519.48% Does the media favor TYRA or MLTX? In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 6 mentions for Tyra Biosciences. MoonLake Immunotherapeutics' average media sentiment score of 0.35 beat Tyra Biosciences' score of 0.19 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of TYRA or MLTX? 84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, TYRA or MLTX? MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTyra BiosciencesN/AN/A-$69.13M-$1.61-9.86MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.29-38.62 Do analysts recommend TYRA or MLTX? Tyra Biosciences presently has a consensus target price of $31.00, suggesting a potential upside of 95.34%. MoonLake Immunotherapeutics has a consensus target price of $79.00, suggesting a potential upside of 58.57%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more risk & volatility, TYRA or MLTX? Tyra Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. SummaryMoonLake Immunotherapeutics beats Tyra Biosciences on 12 of the 16 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Tyra Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TYRA vs. The Competition Export to ExcelMetricTyra BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$820.27M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-9.8610.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book2.225.474.674.68Net Income-$69.13M$153.61M$119.07M$226.08M7 Day Performance-2.88%-2.00%-1.83%-1.04%1 Month Performance-44.06%-7.47%-3.62%1.04%1 Year Performance43.49%31.80%31.63%26.28% Tyra Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TYRATyra Biosciences3.0819 of 5 stars$15.87-2.1%$31.00+95.3%+40.8%$820.27MN/A-9.8620MLTXMoonLake Immunotherapeutics3.2708 of 5 stars$49.82+1.0%$79.00+58.6%+16.8%$3.18BN/A-38.622HCMHUTCHMED1.1549 of 5 stars$17.96+7.2%$20.55+14.4%-3.1%$3.13B$838M0.001,988Analyst DowngradeNews CoverageGap UpAGIOAgios Pharmaceuticals3.3113 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390DYNDyne Therapeutics3.3831 of 5 stars$29.99+1.0%$51.40+71.4%+181.6%$3.05BN/A-8.42100Insider TradeAnalyst RevisionVRNAVerona Pharma2.5968 of 5 stars$38.85+2.0%$43.83+12.8%+163.7%$3.04B$460,000.000.0030Positive NewsPTCTPTC Therapeutics2.5538 of 5 stars$41.96+6.6%$42.00+0.1%+89.3%$3.04B$937.82M0.001,410Analyst DowngradeEWTXEdgewise Therapeutics1.7269 of 5 stars$31.95+1.4%$38.40+20.2%+396.9%$3.03BN/A-21.3060BHCBausch Health Companies3.4347 of 5 stars$8.20+0.1%$7.75-5.4%+16.3%$3.01B$8.76B-17.0720,270Positive NewsMRUSMerus1.9713 of 5 stars$42.93-1.3%$86.70+102.0%+76.7%$2.98B$43.95M0.0037Analyst ForecastXENEXenon Pharmaceuticals3.4913 of 5 stars$39.34+1.3%$57.45+46.0%+35.2%$2.96B$9.43M0.00251Analyst Revision Related Companies and Tools Related Companies MLTX Alternatives HCM Alternatives AGIO Alternatives DYN Alternatives VRNA Alternatives PTCT Alternatives EWTX Alternatives BHC Alternatives MRUS Alternatives XENE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TYRA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
